According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current Operating Margin is -71.92%. At the end of 2021 the company had an Operating Margin of -71.92%.
Year | Operating Margin | Change |
---|---|---|
2021 | -71.92% | 593.51% |
2020 | -10.37% | -68.96% |
2019 | -33.42% | -56.75% |
2018 | -77.27% | -82.56% |
2017 | -443.18% | 39.73% |
2016 | -317.16% | -49.27% |
2015 | -625.16% | 216.52% |
2014 | -197.51% | -18.17% |
2013 | -241.38% | 615.2% |
2012 | -33.75% | -92.25% |
2011 | -435.62% | -26.13% |
2010 | -589.73% | -92.84% |
2009 | -8,239.43% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Pfizer PFE | 34.61% | -148.12% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | 14.36% | -119.97% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | -55.07% | -23.43% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -20.53% | -71.45% | ๐ฎ๐ฑ Israel |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.